SCHEMBL13629339

SCHEMBL13629339

CCc1ccc(NS(=O)(=O)c2ccc(F)cc2Cl)cc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.51
PFKFB3 Q16875 1/20 0.47
HTR6 P50406 2/20 0.46
LMNA P02545 2/20 0.45
HTT P42858 2/20 0.45
SGK1 O00141 1/20 0.45
FABP4 P15090 1/20 0.45
FABP5 Q01469 1/20 0.45
CDK1 P06493 1/20 0.44
CCNB1 P14635 1/20 0.44
CCNA2 P20248 1/20 0.44
CDK2 P24941 1/20 0.44
CDK7 P50613 1/20 0.44
CCNH P51946 1/20 0.44
CCNA1 P78396 1/20 0.44
MCL1 Q07820 1/20 0.44
MAPT P10636 2/20 0.43
ALDH1A1 P00352 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PPARG P37231 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629290 0.88 BRD4 (0.52) BRD4PFKFB3HTR6SGK1FABP4
SCHEMBL13629322 0.84 CDK1 (0.51) LMNAHTTSGK1CDK1CCNB1
SCHEMBL13629320 0.83 SLC22A12 (0.54) BRD4LMNAMAPTALDH1A1
SCHEMBL13615118 0.82 BRD4 (0.51) BRD4PFKFB3HTR6HTTSGK1
SCHEMBL13629428 0.81 SLC22A12 (0.48) BRD4LMNASGK1CDK1CCNB1
SCHEMBL13629329 0.79 ALDH1A1 (0.65) LMNAHTTCDK1CCNB1CCNA2
SCHEMBL13629411 0.78 PPARG (0.55) LMNACDK1CCNB1CCNA2CDK2
SCHEMBL13629401 0.78 ALDH1A1 (0.65) BRD4LMNACDK1CCNB1CCNA2
SCHEMBL14403175 0.77 PFKFB3 (0.58) BRD4PFKFB3LMNACDK1CCNB1
SCHEMBL13629465 0.77 LMNA (0.54) LMNACDK1CCNB1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK BRD4 548/4885PFKFB3 482/4885HTR6 1515/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK BRD4 674/4885PFKFB3 467/4885HTR6 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.